Trial Outcomes & Findings for Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey (NCT NCT06680206)

NCT ID: NCT06680206

Last Updated: 2026-01-22

Results Overview

Number of participants according to migraine medication type: 1) as prescription drug only, 2) as OTC only or 3) as both prescription drug and OTC based on the use of migraine medication classes is reported in this outcome measure. Analysis was performed using inverse probability treatment weighting (IPTW) method to adjust for confounding by the covariates.

Recruitment status

COMPLETED

Target enrollment

1395 participants

Primary outcome timeframe

At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Results posted on

2026-01-22

Participant Flow

In this retrospective observational study, data of participants who used rimegepant or triptans for migraine (diagnosed by physician) in Year 2023, was retrieved from United States National Health and Wellness Survey (NHWS). Retrieved retrospective data was evaluated in approximately 1.41 months (from study start date: 10-Oct-2024 to study completion date: 20-Nov-2024) per objectives of the study.

Participant milestones

Participant milestones
Measure
Rimegepant
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Triptans
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Overall Study
STARTED
137
1258
Overall Study
Inverse Probability Treatment Weighting (IPTW) Adjustment
135
1260
Overall Study
Sensitivity Analysis
105
1258
Overall Study
Sensitivity Analysis IPTW Adjustment
103
1257
Overall Study
COMPLETED
137
1258
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Rimegepant
n=137 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Triptans
n=1258 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Total
n=1395 Participants
Total of all reporting groups
Age, Customized
18-29 years
25 Participants
n=270 Participants
178 Participants
n=4 Participants
203 Participants
n=9 Participants
Age, Customized
30-39 years
26 Participants
n=270 Participants
185 Participants
n=4 Participants
211 Participants
n=9 Participants
Age, Customized
40-49 years
39 Participants
n=270 Participants
249 Participants
n=4 Participants
288 Participants
n=9 Participants
Age, Customized
50-59 years
29 Participants
n=270 Participants
282 Participants
n=4 Participants
311 Participants
n=9 Participants
Age, Customized
60-69 years
13 Participants
n=270 Participants
248 Participants
n=4 Participants
261 Participants
n=9 Participants
Age, Customized
70-79 years
5 Participants
n=270 Participants
108 Participants
n=4 Participants
113 Participants
n=9 Participants
Age, Customized
80-89 years
0 Participants
n=270 Participants
8 Participants
n=4 Participants
8 Participants
n=9 Participants
Sex: Female, Male
Female
124 Participants
n=270 Participants
1016 Participants
n=4 Participants
1140 Participants
n=9 Participants
Sex: Female, Male
Male
13 Participants
n=270 Participants
242 Participants
n=4 Participants
255 Participants
n=9 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
18 Participants
n=270 Participants
122 Participants
n=4 Participants
140 Participants
n=9 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
119 Participants
n=270 Participants
1136 Participants
n=4 Participants
1255 Participants
n=9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=270 Participants
0 Participants
n=4 Participants
0 Participants
n=9 Participants
Race/Ethnicity, Customized
Race · Black
12 Participants
n=270 Participants
114 Participants
n=4 Participants
126 Participants
n=9 Participants
Race/Ethnicity, Customized
Race · White
116 Participants
n=270 Participants
1062 Participants
n=4 Participants
1178 Participants
n=9 Participants
Race/Ethnicity, Customized
Race · Other
9 Participants
n=270 Participants
82 Participants
n=4 Participants
91 Participants
n=9 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Number of participants according to migraine medication type: 1) as prescription drug only, 2) as OTC only or 3) as both prescription drug and OTC based on the use of migraine medication classes is reported in this outcome measure. Analysis was performed using inverse probability treatment weighting (IPTW) method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC])
Prescription Drug only
682 Participants
74 Participants
Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC])
Prescription drug and OTC
578 Participants
61 Participants
Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC])
OTC only
0 Participants
0 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Number of participants according to migraine treatment type: 1) acute use only, 2) prevention use only, or 3) both acute and prevention use based on the use of migraine medication classes is reported in this outcome measure. Acute treatments included: triptans, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment; preventive treatment included: anticonvulsants, beta blocker, antidepressant, calcitonin gene-related peptide antibodies monoclonal antibodies (CGRP mAb), botox, and gepant \[prevention treatment including Nurtec\]). Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Migraine Treatment Type (Acute or Prevention)
Acute use only
837 Participants
0 Participants
Number of Participants According to Migraine Treatment Type (Acute or Prevention)
Prevention use only
0 Participants
0 Participants
Number of Participants According to Migraine Treatment Type (Acute or Prevention)
Both Acute and Prevention use
423 Participants
135 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Total number of distinct acute migraine agent drug classes used by participants is reported as mean in this outcome measure. Acute migraine agents included: triptans, NSAIDs, opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Total Number of Acute Migraine Agent Drug Classes Used
2.2 Drug classes per participant
Standard Deviation 1.2
2.1 Drug classes per participant
Standard Deviation 1.2

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Number of participants categorized by the number of distinct acute migraine agent drug classes used is reported in this outcome measure. Categories included 1 drug class, 2 or more drug classes, and 3 or more drug classes. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Number of Acute Migraine Agent Drug Classes Used
3 or more drug classes
406 Participants
40 Participants
Number of Participants According to Number of Acute Migraine Agent Drug Classes Used
1 drug class
431 Participants
51 Participants
Number of Participants According to Number of Acute Migraine Agent Drug Classes Used
2 or more drug classes
829 Participants
84 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. The analysis was performed on all participants reported under Overall Number of Participants Analyzed.

Preventive migraine agents included: anticonvulsants, beta blocker, antidepressant, CGRP mAb, botox, and gepant \[prevention treatment including Nurtec\]. Total number of distinct preventive migraine agent drug classes used by participants is reported as mean in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Total Number of Prevention Migraine Agent Drug Classes Used
0.5 Drug classes per participant
Standard Deviation 0.8
1.5 Drug classes per participant
Standard Deviation 0.7

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. The analysis was performed on all participants reported under Overall Number of Participants Analyzed.

Number of participants categorized by the number of distinct prescription preventive migraine agent drug classes used reported in this outcome measure. Categories included use of 1 drug class, 2 or more drug classes, and 3 or more drug classes. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used
1 drug class
297 Participants
79 Participants
Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used
2 or more drug classes
126 Participants
56 Participants
Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used
3 or more drug classes
25 Participants
12 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Number of participants according to current migraine treatments on drug classes including: Nurtec (rimegepant) only, acute agents, triptans, NSAIDs, opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment (aspirin lysine/metoclopramide hydrochloride monohydrate or indometacin/caffeine/prochlorperazine), prevention agents (anticonvulsants, beta-blocker, antidepressant, CGRP mAb, botox, and gepant) are reported in this outcome measure. One participant could receive more than one migraine treatment. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Current Migraine Treatments
Nurtec (rimegepant) only
0 Participants
135 Participants
Number of Participants According to Current Migraine Treatments
Acute agents
1259 Participants
135 Participants
Number of Participants According to Current Migraine Treatments
Triptans
1260 Participants
0 Participants
Number of Participants According to Current Migraine Treatments
NSAIDs
187 Participants
22 Participants
Number of Participants According to Current Migraine Treatments
Opioids
132 Participants
10 Participants
Number of Participants According to Current Migraine Treatments
Barbiturates
96 Participants
6 Participants
Number of Participants According to Current Migraine Treatments
Ergots
35 Participants
4 Participants
Number of Participants According to Current Migraine Treatments
Gepants (acute; including Nurtec)
33 Participants
135 Participants
Number of Participants According to Current Migraine Treatments
Ditan
3 Participants
0 Participants
Number of Participants According to Current Migraine Treatments
Combination analgesics
206 Participants
18 Participants
Number of Participants According to Current Migraine Treatments
Other (acute treatment)
20 Participants
2 Participants
Number of Participants According to Current Migraine Treatments
Prevention agents
423 Participants
135 Participants
Number of Participants According to Current Migraine Treatments
Anticonvulsants
191 Participants
18 Participants
Number of Participants According to Current Migraine Treatments
Beta blocker
45 Participants
2 Participants
Number of Participants According to Current Migraine Treatments
Antidepressant
53 Participants
8 Participants
Number of Participants According to Current Migraine Treatments
CGRP mAb
188 Participants
28 Participants
Number of Participants According to Current Migraine Treatments
Botox
76 Participants
15 Participants
Number of Participants According to Current Migraine Treatments
Gepant (prevention treatment including Nurtec)
29 Participants
135 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.

Number of participants according to treatment satisfaction for the migraine drug classes including: acute agents, NSAIDs, opioids, barbiturates, ergots, gepants (acute), ditans, combination analgesics, other, prevention agents, anticonvulsants, beta blockers, antidepressants, CGRPs mAb, botox, and gepant reported in this outcome measure. Treatment satisfaction for each of the migraine drug class was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Antidepressants · Very dissatisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Antidepressants · Somewhat dissatisfied
0 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Antidepressants · Neither dissatisfied nor satisfied
17 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Antidepressants · Somewhat satisfied
11 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Antidepressants · Very satisfied
13 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Antidepressants · Extremely satisfied
5 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - CGRPs mAb · Extremely dissatisfied
2 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - CGRPs mAb · Very dissatisfied
1 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - CGRPs mAb · Somewhat dissatisfied
4 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - CGRPs mAb · Neither dissatisfied nor satisfied
51 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - CGRPs mAb · Somewhat satisfied
47 Participants
5 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - CGRPs mAb · Very satisfied
34 Participants
9 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - CGRPs mAb · Extremely satisfied
49 Participants
12 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Botox · Extremely dissatisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Botox · Very dissatisfied
1 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Botox · Somewhat dissatisfied
0 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Botox · Neither dissatisfied nor satisfied
3 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Botox · Somewhat satisfied
33 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Botox · Very satisfied
23 Participants
7 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Botox · Extremely satisfied
16 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepant (prevention treatment including Nurtec) · Extremely dissatisfied
0 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepant (prevention treatment including Nurtec) · Very dissatisfied
0 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepant (prevention treatment including Nurtec) · Somewhat dissatisfied
4 Participants
4 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepant (prevention treatment including Nurtec) · Neither dissatisfied nor satisfied
1 Participants
7 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepant (prevention treatment including Nurtec) · Somewhat satisfied
12 Participants
32 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepant (prevention treatment including Nurtec) · Very satisfied
9 Participants
51 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepant (prevention treatment including Nurtec) · Extremely satisfied
3 Participants
39 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Other (Acute treatment) · Very dissatisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Other (Acute treatment) · Very satisfied
5 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Other (Acute treatment) · Somewhat dissatisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Other (Acute treatment) · Neither dissatisfied nor satisfied
7 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Other (Acute treatment) · Somewhat satisfied
2 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Other (Acute treatment) · Extremely satisfied
0 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Prevention agents · Extremely dissatisfied
28 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Prevention agents · Very dissatisfied
12 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Prevention agents · Somewhat dissatisfied
21 Participants
9 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Prevention agents · Neither dissatisfied nor satisfied
106 Participants
14 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Prevention agents · Somewhat satisfied
107 Participants
29 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Prevention agents · Very satisfied
85 Participants
47 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Prevention agents · Extremely satisfied
64 Participants
33 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Anticonvulsants · Extremely dissatisfied
25 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Anticonvulsants · Very dissatisfied
4 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Anticonvulsants · Somewhat dissatisfied
11 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Anticonvulsants · Neither dissatisfied nor satisfied
38 Participants
4 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Anticonvulsants · Very satisfied
43 Participants
4 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Anticonvulsants · Somewhat satisfied
47 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Anticonvulsants · Extremely satisfied
23 Participants
5 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Beta-blockers · Extremely dissatisfied
7 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Beta-blockers · Very dissatisfied
6 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Beta-blockers · Somewhat dissatisfied
2 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Beta-blockers · Neither dissatisfied nor satisfied
2 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Beta-blockers · Somewhat satisfied
11 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Opioids · Very satisfied
17 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Beta-blockers · Very satisfied
6 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Beta-blockers · Extremely satisfied
11 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Acute agents · Extremely dissatisfied
97 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Acute agents · Very dissatisfied
45 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Acute agents · Somewhat dissatisfied
92 Participants
6 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Acute agents · Neither dissatisfied nor satisfied
145 Participants
14 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Acute agents · Somewhat satisfied
351 Participants
36 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Acute agents · Very satisfied
341 Participants
42 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Acute agents · Extremely satisfied
188 Participants
31 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - NSAIDs · Extremely dissatisfied
15 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - NSAIDs · Very dissatisfied
13 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - NSAIDs · Somewhat dissatisfied
8 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - NSAIDs · Neither dissatisfied nor satisfied
24 Participants
4 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - NSAIDs · Somewhat satisfied
65 Participants
10 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Opioids · Extremely satisfied
7 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Barbiturates · Extremely dissatisfied
6 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Barbiturates · Very dissatisfied
40 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - NSAIDs · Very satisfied
45 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - NSAIDs · Extremely satisfied
17 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Opioids · Extremely dissatisfied
22 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Opioids · Very dissatisfied
13 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Opioids · Somewhat dissatisfied
5 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Opioids · Neither dissatisfied nor satisfied
45 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Opioids · Somewhat satisfied
23 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Barbiturates · Somewhat dissatisfied
11 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Barbiturates · Neither dissatisfied nor satisfied
10 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepants (acute; including Nurtec) · Somewhat satisfied
14 Participants
32 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepants (acute; including Nurtec) · Very satisfied
8 Participants
52 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepants (acute; including Nurtec) · Extremely satisfied
2 Participants
38 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ditans · Extremely dissatisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Barbiturates · Somewhat satisfied
18 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Barbiturates · Very satisfied
9 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Barbiturates · Extremely satisfied
2 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ditans · Very dissatisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ergots · Extremely dissatisfied
0 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ergots · Very dissatisfied
2 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ergots · Somewhat dissatisfied
0 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ergots · Neither dissatisfied nor satisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ergots · Somewhat satisfied
1 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ergots · Very satisfied
1 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ergots · Extremely satisfied
31 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepants (acute; including Nurtec) · Extremely dissatisfied
6 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Antidepressants · Extremely dissatisfied
7 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepants (acute; including Nurtec) · Very dissatisfied
0 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepants (acute; including Nurtec) · Somewhat dissatisfied
0 Participants
4 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Gepants (acute; including Nurtec) · Neither dissatisfied nor satisfied
3 Participants
6 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Combination Analgesics · Somewhat dissatisfied
21 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ditans · Somewhat dissatisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ditans · Neither dissatisfied nor satisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ditans · Somewhat satisfied
2 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ditans · Very satisfied
1 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Ditans · Extremely satisfied
0 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Combination Analgesics · Extremely dissatisfied
11 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Combination Analgesics · Very dissatisfied
13 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Combination Analgesics · Neither dissatisfied nor satisfied
40 Participants
4 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Combination Analgesics · Somewhat satisfied
71 Participants
6 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Combination Analgesics · Very satisfied
30 Participants
5 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Combination Analgesics · Extremely satisfied
20 Participants
0 Participants
Number of Participants According to Treatment Satisfaction of Migraine Drug Class
Current migraine satisfactions - Other (Acute treatment) · Extremely dissatisfied
6 Participants
0 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Analysis was performed on all participants reported under "Overall Number of Participants Analyzed".

Participants were categorized based on current use of OTC migraine treatments, including analgesics (acetaminophen only), analgesics (combination), NSAIDs, and other OTCs.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Current Migraine Treatments on OTC Class
Analgesics (acetaminophen only)
198 Participants
34 Participants
Number of Participants According to Current Migraine Treatments on OTC Class
Analgesics (Combination)
221 Participants
28 Participants
Number of Participants According to Current Migraine Treatments on OTC Class
NSAIDs
320 Participants
32 Participants
Number of Participants According to Current Migraine Treatments on OTC Class
Other
4 Participants
0 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Number of participants according to treatment satisfaction for analgesics (acetaminophen only) is reported in this outcome measure. Treatment satisfaction was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=198 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=34 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Extremely dissatisfied
13 Participants
3 Participants
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Very dissatisfied
3 Participants
2 Participants
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Somewhat dissatisfied
13 Participants
6 Participants
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Neither dissatisfied nor satisfied
44 Participants
10 Participants
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Somewhat satisfied
93 Participants
12 Participants
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Very satisfied
24 Participants
1 Participants
Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only)
Extremely satisfied
8 Participants
0 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Number of participants according to treatment satisfaction for rimegepant or triptans is reported in this outcome measure. Treatment satisfaction was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Extremely dissatisfied
74 Participants
1 Participants
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Very dissatisfied
46 Participants
1 Participants
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Somewhat dissatisfied
69 Participants
4 Participants
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Neither dissatisfied nor satisfied
101 Participants
7 Participants
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Somewhat satisfied
333 Participants
32 Participants
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Very satisfied
389 Participants
51 Participants
Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans
Extremely satisfied
248 Participants
39 Participants

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

RAND-36=standardized survey evaluating 8 domains of functional health and well-being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Score for each of the 8 domains were scaled from 0=worst condition to 100=best condition, higher scores indicated better health status. These 8 domains were summarized as summary scores: physical component scores (derived from physical functioning, role physical, bodily pain, general health), mental component scores (derived from social functioning, role emotional mental health and vitality) and global health composite score (derived from physical and mental component scores). Each of the summary scores were standardized to a T-score with mean=50 and SD=10. Scores ranged from 0 to 100, where 0 (worst condition) to 100 (best condition), where higher scores represent better health status. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Primary Analysis
Mental summary composite T score
37.1 Units on a scale
Standard Deviation 12.6
38.2 Units on a scale
Standard Deviation 12
Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Primary Analysis
Physical summary composite T score
39.8 Units on a scale
Standard Deviation 11.9
39.5 Units on a scale
Standard Deviation 12
Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Primary Analysis
Global health composite T score
36.7 Units on a scale
Standard Deviation 12.7
37.2 Units on a scale
Standard Deviation 12.4

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

EQ-5D-5L is participant completed questionnaire that consisted of two components: a five-item health state profile and visual analog scale (VAS). EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension had 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems and 5= extreme problems. Responses to 5 dimensions comprised health state/a single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses) had unique predefined utility index value assigned to it per US value sets, by EuroQol. Index scores ranged from -0.59 to 1; where 1 =best possible health state. Negative values= health states perceived as worse than dead, (death=0). Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Index Score - Primary Analysis
0.7 Units on a scale
Standard Deviation 0.2
0.7 Units on a scale
Standard Deviation 0.2

PRIMARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

The EQ-5D-5L is a participant completed questionnaire that consisted of two components: a five-item health state profile and a VAS. EQ-5D VAS was used to record participant's rating for his/her current health state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
EQ-5D-5L Visual Analog Scale (VAS) Score - Primary Analysis
66.8 Units on a scale
Standard Deviation 20.6
66.5 Units on a scale
Standard Deviation 21.8

PRIMARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

The WPAI is a standardized Patient reported outcome (PRO) that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage of work time missed ranged from 0 (no impairment/high productivity) to-100% (total loss of work productivity) with higher score indicating greater impairment and less productivity. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage of Work Time Missed in Past 7 Days Based on Work Productivity and Activity Impairment - General Health (WPAI-GH) Questionnaire- Primary Analysis
9.6 Percentage work time missed
Standard Deviation 19.9
7.1 Percentage work time missed
Standard Deviation 17.1

PRIMARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

The WPAI is a standardized PRO that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage impairment experienced ranged from 0 (no impairment/high productivity/high impairment) to 100% (total loss of work productivity) with higher score indicating greater impairment and less productivity. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage Impairment Experienced While at Work in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
27.6 Percentage impairment
Standard Deviation 25.4
29.4 Percentage impairment
Standard Deviation 26.2

PRIMARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

The WPAI is a standardized PRO that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage overall work impairment experienced ranged from 0 (no impairment/high productivity/high impairment) to 100% (total loss of work productivity/high impairment) with higher score indicating greater impairment and less productivity. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage Overall Work Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
31.1 Percentage work impairment
Standard Deviation 28.5
31.6 Percentage work impairment
Standard Deviation 28.1

PRIMARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.

The WPAI is a standardized PRO that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage of total activity impairment ranged from 0 (no impairment/high productivity) to 100% (total loss of work productivity/high impairment) with higher score indicating greater impairment and less productivity. In this outcome measure, percentage total activity impairment among total population, employed, unemployed and disabled is reported. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
Total activity impairment
37.6 Percentage activity impairment
Standard Deviation 28.6
41.3 Percentage activity impairment
Standard Deviation 29.3
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
Activity impairment among employed
31.1 Percentage activity impairment
Standard Deviation 26.5
31.8 Percentage activity impairment
Standard Deviation 26.4
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
Activity impairment among unemployed
41.6 Percentage activity impairment
Standard Deviation 27.9
48.8 Percentage activity impairment
Standard Deviation 27.4
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Primary Analysis
Activity impairment among disabled
69.4 Percentage activity impairment
Standard Deviation 21
70 Percentage activity impairment
Standard Deviation 23.9

PRIMARY outcome

Timeframe: 3 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

MIDAS is a retrospective, self-administered, 7-item questionnaire that measured headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provided the number of missed work or school days (MIDAS Item 1); missed household chores days (MIDAS Item 2); missed social or leisure activity days (MIDAS Item 3); and days with productivity loss at work or school (MIDAS Item 4), days with productivity loss in household work (MIDAS Item 5), frequency of headaches (MIDAS Item 6) and the intensity of the headache pain (MIDAS Item 7). The score ranged from 0 (no disability) to 90 (maximum disability) for each of individual item scores. The 5 item scores (Item 1 to Item 5) were summed to compute the MIDAS total score ranging from 0 (no disability) to 450 (maximum disability). Lower scores indicate less headache-related disability. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS Item 1 (MGMIDAS1)
2.1 Units on a scale
Standard Deviation 6.1
2.0 Units on a scale
Standard Deviation 5.5
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS Item 2 (MGMIDAS2)
4.9 Units on a scale
Standard Deviation 9.6
6.8 Units on a scale
Standard Deviation 12.2
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS Item 4 (MGMIDAS4)
7.6 Units on a scale
Standard Deviation 10.4
8.8 Units on a scale
Standard Deviation 11.6
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS (Total score)
26.8 Units on a scale
Standard Deviation 36
32.1 Units on a scale
Standard Deviation 40.8
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS Item 3 (MGMIDAS3)
7.2 Units on a scale
Standard Deviation 9.7
9.9 Units on a scale
Standard Deviation 13.5
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS Item 5 (MGMIDAS5)
5.0 Units on a scale
Standard Deviation 10.4
4.7 Units on a scale
Standard Deviation 8.3
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS Item 6 (MGMIDAS6)
16.6 Units on a scale
Standard Deviation 19.8
21.8 Units on a scale
Standard Deviation 23.0
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Primary Analysis
MIDAS Item 7 (MGMIDAS7)
6.9 Units on a scale
Standard Deviation 1.9
6.9 Units on a scale
Standard Deviation 1.8

PRIMARY outcome

Timeframe: 3 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

MIDAS is a retrospective, self-administered, 7-item questionnaire that measured headache-related disability as days with lost time or productivity due to headache from paid work or school, household work, and non-work activities. Participants were categorized according to MIDAS scores as Grade I = Little or No Disability (Score: 0-5), Grade II= Mild Disability (Score: 6-10), Grade III = Moderate Disability (Score: 11-20), Grade IV =severe disability (Score: \>=21). Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to MIDAS Grade- Primary Analysis
MIDAS Grade I
363 Participants
36 Participants
Number of Participants According to MIDAS Grade- Primary Analysis
MIDAS Grade II
138 Participants
20 Participants
Number of Participants According to MIDAS Grade- Primary Analysis
MIDAS Grade III
238 Participants
25 Participants
Number of Participants According to MIDAS Grade- Primary Analysis
MIDAS Grade IV
521 Participants
54 Participants

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Primary Analysis
334 Participants
36 Participants

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, "Overall Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.

Number of ER visits within the last six months due to any cause among those who had at least 1 ER visit reported as mean in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=334 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=36 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of ER Visits in Past 6 Months- Primary Analysis
0.5 ER visits
Standard Deviation 1.4
0.5 ER visits
Standard Deviation 1.1

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Hospitalizations in Past 6 Months- Primary Analysis
147 Participants
15 Participants

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, "Overall Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.

Mean number of hospitalizations within the last six months due to any cause among those who had at least 1 hospitalization is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=147 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=15 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Hospitalizations in Past 6 Months - Primary Analysis
2.5 Hospitalizations
Standard Deviation 6.6
1.5 Hospitalizations
Standard Deviation 1.1

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Family Practitioner Visits in Past 6 Months- Primary Analysis
979 Participants
102 Participants

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, "Overall Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.

Mean number of family practitioner visits within the last six months due to any cause among those who had at least 1 family practitioner visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=979 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=102 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Family Practitioner Visits in Past 6 Months- Primary Analysis
2 Family Practitioner Visits
Standard Deviation 2
2 Family Practitioner Visits
Standard Deviation 1.2

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Cardiologist Visits in Past 6 Month- Primary Analysis
130 Participants
21 Participants

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, "Overall Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.

Mean number of cardiologist visits within the last six months due to any cause among those who had at least 1 cardiologist visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=130 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=21 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Cardiologist Visits in Past 6 Months- Primary Analysis
1.8 Cardiologist Visits
Standard Deviation 1.5
1.6 Cardiologist Visits
Standard Deviation 1.2

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 month of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Neurologist Visits in Past 6 Months - Primary Analysis
374 Participants
72 Participants

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, "Overall Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.

Mean number of neurologist visits within the last six months due to any cause among those who had at least 1 neurologist visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=374 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=72 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Neurologist Visits in Past 6 Months- Primary Analysis
2 Neurologist Visits
Standard Deviation 1.3
2.6 Neurologist Visits
Standard Deviation 6

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1260 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=135 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis
1228 Participants
132 Participants

PRIMARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study and were adjusted using IPTW method (pseudo-set); hence, numbers of participants are different here from those presented in participant flow and baseline section. Here, "Overall Number of Participants Analyzed" signifies number of participants evaluable for this outcome measure.

Mean number of traditional healthcare provider visits within the last six months due to due to any cause among those who had at least 1 healthcare provider visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariate.

Outcome measures

Outcome measures
Measure
Triptans
n=1228 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=132 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Traditional Healthcare Provider Visits in Past 6 Months- Primary Analysis
7.8 Traditional Healthcare Provider Visits
Standard Deviation 8.1
9.5 Traditional Healthcare Provider Visits
Standard Deviation 10.6

SECONDARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

RAND-36=standardized survey evaluating 8 domains of functional health and well-being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Score for each of the 8 domains were scaled from 0=worst condition to 100=best condition, higher scores indicated better health status. These 8 domains were summarized as summary scores: physical component scores (derived from physical functioning, role physical, bodily pain, general health), mental component scores (derived from social functioning, role emotional mental health and vitality) and global health composite score (derived from physical and mental component scores). Each of the summary scores were standardized to a T-score with mean=50 and SD=10. Scores ranged from 0 to 100, where 0 (worst condition) to 100 (best condition), where higher scores represent better health status. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Sensitivity Analysis.
Mental summary composite T score
38.1 Units on a scale
Standard Deviation 12.4
39.1 Units on a scale
Standard Deviation 11.9
Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Sensitivity Analysis.
Physical summary composite T score
41.2 Units on a scale
Standard Deviation 11.6
40.6 Units on a scale
Standard Deviation 11.5
Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Sensitivity Analysis.
Global health composite T score
38 Units on a scale
Standard Deviation 12.4
38.3 Units on a scale
Standard Deviation 12

SECONDARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

EQ-5D-5L is participant completed questionnaire that consisted of two components: a five-item health state profile and visual analog scale (VAS). EQ-5D health state profile had 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension had 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems and 5= extreme problems. Responses to 5 dimensions comprised health state/a single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses) had unique predefined utility index value assigned to it per US value sets, by EuroQol. Index scores ranged from -0.59 to 1; where 1 =best possible health state. Negative values= health states perceived as worse than dead, (death=0). Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) Index Score- Sensitivity Analysis
0.7 Units on a scale
Standard Deviation 0.2
0.8 Units on a scale
Standard Deviation 0.2

SECONDARY outcome

Timeframe: At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

The EQ-5D-5L is a participant completed questionnaire that consisted of two components: a five-item health state profile and a VAS. EQ-5D VAS was used to record participant's rating for his/her current health state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
EQ-5D-5L Visual Analog Scale (VAS) Score- Sensitivity Analysis
68.9 Units on a scale
Standard Deviation 19.5
69.6 Units on a scale
Standard Deviation 20.2

SECONDARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

The WPAI is a standardized PRO that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage of work time missed ranged from 0 (no impairment/high productivity) to 100% (high impairment/total loss of work productivity) with higher score indicating greater impairment and less productivity. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage of Work Time Missed in Past 7 Days Based on Work Productivity and Activity Impairment - General Health (WPAI-GH) Questionnaire- Sensitivity Analysis
8.8 Percentage work time missed
Standard Deviation 19.2
6.4 Percentage work time missed
Standard Deviation 14

SECONDARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

The WPAI is a standardized PRO that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage impairment experienced ranged from 0 (no impairment/high productivity) to 100% (high impairment/total loss of work productivity) with higher score indicating greater impairment and less productivity. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage Impairment Experienced While at Work in Past 7 Days Based on WPAI-GH Questionnaire-Sensitivity Analysis
25 Percentage impairment
Standard Deviation 24.7
28.1 Percentage impairment
Standard Deviation 26.4

SECONDARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

The WPAI is a standardized PRO that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage overall work impairment experienced ranged from 0 (no impairment/high productivity) to 100% (high impairment/total loss of work productivity) with higher score indicating greater impairment and less productivity. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage Overall Work Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Sensitivity Analysis
28.4 Percentage work impairment
Standard Deviation 27.9
30.4 Percentage work impairment
Standard Deviation 28.5

SECONDARY outcome

Timeframe: 7 days before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

The WPAI is a standardized PRO that assessed the previous 7 days of completing the questionnaire. WPAI:GH is a self-reported measure of work productivity and impairment, which had four scores: absenteeism (work time missed); presenteeism (impairment at work/reduced on the job effectiveness); work productivity loss (overall work impairment/absenteeism plus presenteeism); and total activity impairment. The scores for percentage of total activity impairment ranged from 0 (no impairment/high productivity) to100% (high impairment/total loss of work productivity) with higher score indicating greater impairment and less productivity. In this outcome measure, percentage total activity impairment among total population, employed, unemployed and disabled is reported. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Sensitivity Analysis
Total activity impairment
34.4 Percentage activity impairment
Standard Deviation 28.3
37.6 Percentage activity impairment
Standard Deviation 28
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Sensitivity Analysis
Activity impairment among employed
28.3 Percentage activity impairment
Standard Deviation 25.9
30.6 Percentage activity impairment
Standard Deviation 25.6
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Sensitivity Analysis
Activity impairment among unemployed
38.7 Percentage activity impairment
Standard Deviation 28.3
44.4 Percentage activity impairment
Standard Deviation 27.7
Percentage Total Activity Impairment in Past 7 Days Based on WPAI-GH Questionnaire- Sensitivity Analysis
Activity impairment among disabled
68.8 Percentage activity impairment
Standard Deviation 19.3
63.3 Percentage activity impairment
Standard Deviation 26.9

SECONDARY outcome

Timeframe: 3 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

MIDAS is a retrospective, self-administered, 7-item questionnaire that measured headache-related disability as lost time due to headache from paid work or school, household work, and non-work activities. Participants provided the number of missed work or school days (MIDAS Item 1); missed household chores days (MIDAS Item 2); missed social or leisure activity days (MIDAS Item 3); and days with productivity loss at work or school (MIDAS Item 4), days with productivity loss in household work (MIDAS Item 5), frequency of headaches (MIDAS Item 6) and the intensity of the headache pain (MIDAS Item 7). The score ranged from 0 (no disability) to 90 (maximum disability) for each of individual item scores. The 5 item scores (Item 1 to Item 5) were summed to compute the MIDAS total score ranging from 0 (no disability) to 450 (maximum disability). Lower scores indicate less headache-related disability. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS (Total score)
21.6 Units on a scale
Standard Deviation 29.1
25.6 Units on a scale
Standard Deviation 36
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS Item 1 (MGMIDAS1)
1.8 Units on a scale
Standard Deviation 4.9
1.9 Units on a scale
Standard Deviation 5.8
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS Item 2 (MGMIDAS2)
4.1 Units on a scale
Standard Deviation 7.6
4.9 Units on a scale
Standard Deviation 9.3
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS Item 3 (MGMIDAS3)
5.8 Units on a scale
Standard Deviation 7.8
7.8 Units on a scale
Standard Deviation 12.1
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS Item 4 (MGMIDAS4)
6.1 Units on a scale
Standard Deviation 8.6
7 Units on a scale
Standard Deviation 9.8
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS Item 5 (MGMIDAS5)
3.8 Units on a scale
Standard Deviation 8.1
4.1 Units on a scale
Standard Deviation 7.7
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS Item 6 (MGMIDAS6)
14.3 Units on a scale
Standard Deviation 16.8
19.5 Units on a scale
Standard Deviation 21.9
Migraine Disability Assessment Scale (MIDAS) Total Score and Individual Item Scores- Sensitivity Analysis
MIDAS Item 7 (MGMIDAS7)
6.7 Units on a scale
Standard Deviation 1.9
6.7 Units on a scale
Standard Deviation 1.8

SECONDARY outcome

Timeframe: 3 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

MIDAS is a retrospective, self-administered, 7-item questionnaire that measured headache-related disability as days with lost time or productivity due to headache from paid work or school, household work, and non-work activities. Participants were categorized according to MIDAS scores as Grade I = Little or No Disability (Score: 0-5), Grade II= Mild Disability (Score: 6-10), Grade III = Moderate Disability (Score: 11-20), Grade IV =severe disability (Score: \>=21). Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants According to MIDAS Grade - Sensitivity Analysis
MIDAS Grade I
398 Participants
29 Participants
Number of Participants According to MIDAS Grade - Sensitivity Analysis
MIDAS Grade II
159 Participants
17 Participants
Number of Participants According to MIDAS Grade - Sensitivity Analysis
MIDAS Grade III
270 Participants
23 Participants
Number of Participants According to MIDAS Grade - Sensitivity Analysis
MIDAS Grade IV
430 Participants
34 Participants

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Emergency Room (ER) Visits in Past 6 Months- Sensitivity Analysis
301 Participants
27 Participants

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Number of ER visits within the last six months due to any cause among those who had at least 1 ER visit reported as mean in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=301 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=27 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of ER Visits in Past 6 Months- Sensitivity Analysis
1.8 ER visits
Standard Deviation 1.5
1.4 ER visits
Standard Deviation 0.6

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Hospitalizations in Past 6 Months- Sensitivity Analysis
111 Participants
11 Participants

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Mean number of hospitalizations within the last six months due to any cause among those who had at least 1 hospitalization is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=111 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=11 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Hospitalizations in Past 6 Months- Sensitivity Analysis
1.8 Hospitalizations
Standard Deviation 1.3
1.2 Hospitalizations
Standard Deviation 0.4

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Family Practitioner Visits in Past 6 Months- Sensitivity Analysis
976 Participants
76 Participants

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Mean number of family practitioner visits within the last six months due to any cause among those who had at least 1 family practitioner visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=976 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=76 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Family Practitioner Visits in Past 6 Months- Sensitivity Analysis
2 Family Practitioner Visits
Standard Deviation 1.9
1.9 Family Practitioner Visits
Standard Deviation 1.2

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Cardiologist Visits in Past 6 Months- Sensitivity Analysis
137 Participants
14 Participants

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Mean number of cardiologist visits within the last six months due to any cause among those who had at least 1 cardiologist visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=137 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=14 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Cardiologist Visits in Past 6 Months- Sensitivity Analysis
1.7 Cardiologist Visits
Standard Deviation 1.4
1.3 Cardiologist Visits
Standard Deviation 0.5

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 month of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Neurologist Visits in Past 6 Months- Sensitivity Analysis
358 Participants
57 Participants

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Mean number of neurologist visits within the last six months due to any cause among those who had at least 1 neurologist visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=358 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=57 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Neurologist Visits in Past 6 Months- Sensitivity Analysis
1.9 Neurologist Visits
Standard Deviation 1.3
2.6 Neurologist Visits
Standard Deviation 6.4

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW.

Analysis was performed using IPTW method to adjust for confounding by the covariates.

Outcome measures

Outcome measures
Measure
Triptans
n=1257 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=103 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Number of Participants With Traditional Healthcare Provider Visits in Past 6 Months- Sensitivity Analysis
1227 Participants
101 Participants

SECONDARY outcome

Timeframe: 6 months before the survey was taken, during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Population: Analysis population included all eligible participants whose data were retrieved and observed in the study. For sensitivity analysis a subset of rimegepant users with less than 12 days of rimegepant use per month were included and the numbers were adjusted using IPTW method, which created pseudo population, leading to difference from the sample sizes before IPTW. Here, 'Overall Number of Participants Analyzed' signifies number of participants evaluable for this outcome measure.

Mean number of traditional healthcare provider visits within the last six months due to due to any cause among those who had at least 1 healthcare provider visit is reported in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariate.

Outcome measures

Outcome measures
Measure
Triptans
n=1227 Participants
Participants with self-reported diagnosis of migraine currently on triptan use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Rimegepant
n=101 Participants
Participants with self-reported diagnosis of migraine currently on rimegepant use at the time of survey (NHWS in year 2023) were included. No intervention was administered as part of this study.
Mean Number of Traditional Healthcare Provider Visits in Past 6 Months- Sensitivity Analysis
7.7 Traditional Healthcare Provider Visits
Standard Deviation 8
9.2 Traditional Healthcare Provider Visits
Standard Deviation 10.3

Adverse Events

Rimegepant

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Triptans

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Results disclosure agreements

  • Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
  • Publication restrictions are in place

Restriction type: OTHER